ACB News & Events

Aurora Cannabis announced that it has filed a prospectus supplement establishing a new at-the-market offering program that allows the company to issue and sell up to $100M of common shares in the capital of the company from treasury to the public, from time to time, at the company's discretion.

Sees FY26 annual global medical cannabis net revenue up $269M-$281M, driven primarily by 10%-15% annual growth in the global medical cannabis segment; plant propagation revenue to perform in line with traditional seasonal trends, as 65% to 75% of revenues are normally earned in the first half of a calendar year; adjusted gross margins to be strong as the company benefitted from favorable sales mix due to higher global medical cannabis revenue, along with operational efficiencies in Canadian manufacturing sites.